| 0.7963 0.005 (0.64%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.95  |
1-year : | 1.11 |
| Resists | First : | 0.81 |
Second : | 0.95 |
| Pivot price | 0.77 |
|||
| Supports | First : | 0.73 |
Second : | 0.68 |
| MAs | MA(5) : | 0.78 |
MA(20) : | 0.75 |
| MA(100) : | 0.84  |
MA(250) : | 0.91 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 86.2 |
D(3) : | 86.8 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 1.37 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AMRN ] has closed below upper band by 25.7%. Bollinger Bands are 58.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.82 - 0.82 | 0.82 - 0.83 |
| Low: | 0.76 - 0.77 | 0.77 - 0.77 |
| Close: | 0.79 - 0.8 | 0.8 - 0.8 |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Wed, 24 Jul 2024
Amarin (AMRN) Set to Announce Earnings on Wednesday - MarketBeat
Wed, 24 Jul 2024
Amarin (AMRN) Set to Announce Earnings on Wednesday - Defense World
Mon, 22 Jul 2024
Amarin Corporation plc's (NASDAQ:AMRN) Intrinsic Value Is Potentially 29% Above Its Share Price - Yahoo Finance
Mon, 22 Jul 2024
Amarin Co. plc (NASDAQ:AMRN) Shares Sold by Mirae Asset Global Investments Co. Ltd. - Defense World
Wed, 17 Jul 2024
Amarin Corp. (AMRN) Receives National Reimbursement for VAZKEPA in Portugal - StreetInsider.com
Wed, 17 Jul 2024
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 411 (M) |
| Shares Float | 383 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 22.4 (%) |
| Shares Short | 20,430 (K) |
| Shares Short P.Month | 15,810 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.33 |
| Profit Margin | -19 % |
| Operating Margin | -24.1 % |
| Return on Assets (ttm) | -2 % |
| Return on Equity (ttm) | -9.4 % |
| Qtrly Rev. Growth | -34.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.67 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -6.13 |
| PEG Ratio | -0.2 |
| Price to Book value | 0.59 |
| Price to Sales | 1.17 |
| Price to Cash Flow | 253.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|